Christopher Striebich, MD
Rheumatology · Aurora, CONPI 1508956285
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,232 of the $6,759 with a category attached, or 77.4%. 5 manufacturers reported payments, led by Astrazeneca UK Limited at 36.8% of the total. Reporting peaked in 2023 at $5,081 and has fallen 80.0% since, to $1,016 in 2024.
Across 38 payments — averaging $177.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Biogen$2K
- Idorsia Pharmaceuticals US Inc$1K
- Novartis$951
- Amgen$661
Across 124 payments — averaging $16,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$901K
- Novartis$271K
- Astrazeneca UK Limited$268K
- Genentech, Inc.$146K
- AbbVie$113K
- E.r. Squibb & Sons, L.L.C.$108K
- plus $195K from 5 others
What the payments were for
- Travel & lodging$5,23277%
- Food & beverage$1,52723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 13 | $2,485 |
| Biogen | 12 | $1,646 |
| Idorsia Pharmaceuticals US Inc | 3 | $1,016 |
| Novartis | 7 | $951 |
| Amgen | 3 | $661 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,759 in reported general payments places this provider in the 75th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $423,317 |
| Humira(Cf)Adalimumab | 32 | $262,025 |
| Enbrel SureclickEtanercept | 33 | $256,765 |
| XeljanzTofacitinib Citrate | 22 | $120,961 |
| Orencia ClickjectAbatacept | 15 | $96,901 |
| Cosentyx Unoready PenSecukinumab | 13 | $86,757 |
| Teriparatide | 11 | $24,718 |
| Hydroxychloroquine Sulfate | 47 | $2,374 |
| MethotrexateMethotrexate Sodium | 63 | $1,479 |
| Celecoxib | 11 | $612 |
| Prednisone | 54 | $536 |
| Sulfasalazine | 11 | $411 |
| Folic Acid | 16 | $213 |
| Allopurinol | 13 | $147 |
| Alendronate Sodium | 19 | $123 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Aurora
- Larry MorelandAurora$55K
- Sterling WestAurora$42K
- Kevin DeaneAurora$29K
- Vernon HolersAurora$12K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- David TheisColorado Springs$61K
- Rennie McCabeDenver$58K
- Barbara GoldsteinDenver$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.